International Journal of Molecular Medical Science, 2025, Vol.15, No.1, 9-19 http://medscipublisher.com/index.php/ijmms 16 In addition to sensitivity issues, there is a need for standardization in sample processing and analysis protocols to ensure reproducibility across laboratories. Differences in methods for ctDNA extraction, sequencing depth, and data analysis can result in variability in test outcomes, making it difficult to establish consistent diagnostic criteria (Leighl et al., 2019). The lack of standardized procedures can hinder the widespread clinical adoption of these technologies. Moreover, the cost associated with advanced genomic testing remains a significant barrier. High-throughput technologies like NGS involve considerable expenses related to sequencing, data analysis, and infrastructure requirements. While the costs have been decreasing, they still limit access to these tests, especially in resource-limited settings, thus impacting the broader implementation of genomic diagnostics in clinical practice (Paolillo et al., 2016). 6.2 Tumor heterogeneity Tumor heterogeneity presents another substantial challenge in the application of genomic biomarkers for early cancer detection. OSCC, like many cancers, exhibits both inter-tumoral and intra-tumoral heterogeneity, where genetic variations occur between and within tumors, respectively. This heterogeneity complicates the identification of universal biomarkers, as different regions of a tumor may harbor distinct mutations (Nakamura and Yoshino, 2018). As a result, a single biopsy may not capture the full genomic landscape of the tumor, potentially leading to incomplete or misleading results. Furthermore, the clonal evolution of tumors, driven by therapeutic pressures, can alter the genetic makeup of cancer over time. This evolution can lead to the emergence of resistant clones that may not be detected by initial biomarker analysis, resulting in treatment failure (Berger and Mardis, 2018). Monitoring these changes in real-time through techniques like serial ctDNA analysis is possible but remains technically challenging and costly. The spatial heterogeneity of tumors also limits the effectiveness of ctDNA analysis. While ctDNA can provide a more comprehensive overview of genetic changes across different tumor sites, its detection may still be biased by the predominance of mutations from specific clones, potentially underrepresenting others (Perdomo et al., 2017). This highlights the need for advanced bioinformatics approaches and multi-regional sampling to better understand and address the complexities of tumor heterogeneity. 6.3 Regulatory and clinical barriers Beyond technical and biological challenges, regulatory and clinical barriers pose significant hurdles to the adoption of genomic biomarkers in clinical practice. The approval process for new diagnostic tools, including genomic tests, is often lengthy and complex. Regulatory agencies require rigorous validation of the clinical utility and accuracy of these tests, which can delay their availability to patients (Wu and Qu, 2015). Additionally, the interpretation of complex genomic data requires specialized expertise that is not always available in all clinical settings. The integration of genomic information into patient care necessitates training for clinicians in genomics and bioinformatics, which can be a barrier to effective implementation. This gap in knowledge can hinder the ability of healthcare providers to make informed decisions based on genomic test results (Boutros, 2015). Finally, the cost-effectiveness of incorporating genomic biomarkers into routine care remains a contentious issue. Health insurance coverage for such advanced testing is not universally available, creating disparities in access to these technologies. Addressing these economic considerations is crucial to ensure that genomic diagnostics are equitably integrated into cancer care, allowing all patients to benefit from personalized approaches to diagnosis and treatment (Nakamura and Shitara, 2020). 7 Future Directions The future of genomic biomarker research in oral cancer includes the integration of multi-omics approaches, the use of Artificial Intelligence (AI) in biomarker discovery, and overcoming challenges in clinical implementation
RkJQdWJsaXNoZXIy MjQ4ODYzNA==